Friday, December 6

Introductions
7:45 a.m.

Cardiovascular & Coronary Artery Disease — Challenges in 2019
Session I: Evolving New Frontiers Ready for Practice

8:00 a.m. Noninvasive Imaging (3D-US, PET, MRI) & Genetic Stratification (50 Variants)
Predicting Progression of CVD in Over 1000 subjects

8:25 a.m. CTA Imaging in the Full Assessment of Coronary Disease
Noninvasive Approach to Plaque Anatomy, Ischemia & Microcirculation

8:45 a.m. Residual Risk Factors to be Addressed after Cholesterol Management
Inflammatory Biomarkers as a Pragmatic Alarm for Action.

9:05 a.m. Panel Discussion

9:35 a.m. Coffee Break

Session II: Acute Coronary Syndrome Complexities

9:55 a.m. STEMI 1- PCI Culprit Lesion vs Complete Revascularization
With vs Without Cardiogenic Shock

10:15 a.m. STEMI 2- Cardiogenic Shock and Revascularization Strategies
Benefit with “Impella” Mechanical Support and What else?

10:35 a.m. STEMI vs NSTEMI vs STABLE CAD – Optimal Antithrombotics & Timing
DAPT – Stent, Complexity, Comorbidities - and NOACs Role
10:55 a.m.  STEMI vs NSTEMI vs STABLE CAD – Evolving Antithrombotics & Safety
          APT &/or NOAC - CAD Stent & AF, CAD Stent & No Stent, VHD / PHV & AF

11:15 a.m.  Panel Discussion

11:45 a.m.  Lunch

Session III: Systemic Arterial Disease – Chronic Coronary Disease, Stroke and Pulmonary Embolism

12:45 p.m.  Chest Pain Evaluation - Possible vs Probable CAD Evaluation
           CAC vs Stress Test vs CT Angio vs Coronary Angiogram

1:10 p.m.  Managing Steps – Clinical, Anatomy, LV, Ischemia, Plaque, Microcirculation
           Role of PCI vs CABG vs OMT

1:35 p.m.  Complexities of Acute Stroke and Chronic Carotid Artery Stenosis
           Two Entities with Novel Therapeutic Approaches

2:00 p.m.  Pulmonary Emboli - Diagnosis Based on Suspicion
           Management Based on the Acute Severity and Degree of Chronic PH

2:25 p.m.  Panel Discussion

2:55 p.m.  Coffee Break

Session IV: Trends and Challenges of Approaching Prevention – Health Factors

3:15 p.m.  JACC Seminar: Four Challenges To Enhance Eight Health Factors

           1. Pathophysiological Effects,
           2. Mechanistic/Triggering Factors
           3. Role of Preventive Action
           4. Competencies for Training

3:35 p.m.  1. Healthy Weight

3:50 p.m.  2. Nutrition and Diet

4:05 p.m.  3. Physical Activity

4:20 p.m.  4. Tobacco Free

4:35 p.m.  5. Blood Pressure

4:50 p.m.  6. Cholesterol
5:05 p.m.  7. Blood Sugar
5:20 p.m.  8. Psychological Health
5:35 p.m.  Panel Discussion
6:00 p.m.  Adjournment

Saturday, December 7

6:30 a.m.  Continental Breakfast

Cardio-Pulmonary and Electrical Failure 2019
Session V: Myocardial Disease and Heart Failure; Basis for Management

8:00 a.m.  Evolving Imaging (MRI, PET) as Diagnostic & Prognostic Tools
For 7 Myocardial Diseases - Myocarditis, Dilated CM, Hypertrophic CM,
Noncompaction LV, Amyloid CM, Sarcoid & Takotsubo

8:20 a.m.  Evolving Clinical Genetics & Omics in Myocardial Disease
Which or What Subgroup of the 7 Entities Should be Gene Tested

8:35 a.m.  Evolving Understanding of HFrEF vs HFpEF vs HFHiEF (i=Intermediate)
Different Biological Phenotypes and Evolving Therapeutic Options

9:00 a.m.  Evolving Therapeutic Approaches to 3 Challenging Cardiomyopathies:
Myocarditis, Takotsubo, AL/TTR Amyloid and Non-Compaction LV

9:20 a.m.  LVADs – The 2 Upcoming Challenges
1. Indications: not too Late, Not to Early, since Risks are High
2. New Biocompatible Devices, Equal to Transplant Survival?

9:40 a.m.  Panel Discussion

10:10 a.m.  Coffee Break

Session VI: Rhythm Disorders, Contemporary and Future Topics of Focus

10:30 a.m.  Atrial Fibrillation 2019 – The 14 Non-Ablation Clinical Challenges
Quality of Life & Preventing Stroke

10:55 a.m.  Atrial Fibrillation: Catheter Ablation – 4 Questions
Who?, When ?, How?, Results? (CABANA & Others)

11:15 a.m.  Left Atrial Appendage Closure – 4 Questions
Who?, When?, How?, Results?

11:30 a.m.  Ventricular Tachycardia: Catheter Ablation – 4 Questions
Who?, When ?, How?, Results?
11:50 a.m. Follow up of the 3 Recent Device Therapeutic Approaches
   CRTs Strict Indications, Subcutaneous ICDs, Leadless Pacemakers

12:10 p.m. Panel Discussion

12:30 p.m. Lunch

Valvular Heart Disease and Aorta — Challenges in 2019
Session VII: Management of Aortic Valve Disease and Aorta

2:00 p.m. Aortic Valvular Stenosis: 3 Diagnostic and Management Challenges
   - Congenital vs Senile,
   - Asymptomatic vs Symptomatic,
   - Low Flow/Low Gradient: CM 2ary to AS vs Dilated vs Restrictive

2:30 p.m. Aortic Regurgitation: 3 Diagnostic and Management Challenges
   - Associated or not Dilatation of the Aorta
   - Asymptomatic vs Symptomatic
   - EF Low/Intermediate vs Normal

3:00 p.m. The Dilated Thoracic & Abdominal Aorta and Complicating Dissection
   Evolving Understanding of the Basic Biology & Management

3:30 p.m. Coffee Break

Session VIII: Management of Mitral Regurgitation, Tricuspid Regurgitation and Hypertrophic Cardiomyopathy

3:50 p.m. Mitral Regurgitation: 3 Diagnostic and Management Challenges
   - Primary vs Secondary
   - Asymptomatic vs Symptomatic
   - EF Low/Intermediate vs Normal

4:20 p.m. Tricuspid Regurgitation: 3 Diagnostic and Management Challenges
   - Primary vs Secondary to Pulmonary Hypertension
   - Residual from Previous Left Sided Valvular Surgery or not
   - Symptomatic with RVEF Low/Intermediate vs Normal

4:50 p.m. Hypertrophic Cardiomyopathy — 4 Challenging Questions
   Genetics/Acquired, Myectomy/3Types, Natural Hx/ICD, Apical/Aneurysm

5:10 p.m. Discussion

5:30 p.m. Adjourn
6:30 a.m.  Continental Breakfast

Year in Review: The 9 Highlights of Progress in 2019
Session IX: Translational Progress on Genetics, Cellular and Matrix Biology

8:00 a.m.  Part 1. Translational Progress in Genetic Medicine
From Gene Editing in Rhythm Disorders to iPCS in E-Cigarettes Dangers

8:20 a.m.  Part 2. Translational Progress in Cell Regeneration & Degeneration
From Clonal Hematopoiesis to Vascular Regeneration and Disease

8:40 a.m.  Part 3. Translational Progress in Extracellular Matrix
Defensive Remodeling vs Therapeutic Lysis

Section X: Novelties on Diagnostic & Therapeutic Strategies

9:00 a.m.  Part 1. Evolving 18 F Fluoride PET – Clinical and Research Applications
Aortic Valvular Stenosis, Heart & Vascular Macrophage Infiltration

9:20 a.m.  Part 2. Evolving Cardiac MRI - Clinical and Research Applications
Post Myocardial Infarction, Early Chemotherapy Toxicity

9:40 a.m.  Part 3. Evolving Diagnostic Tools – Evaluation of the Microcirculation
The Ignored Frequent Microvascular Syndromes

10:00 a.m.  Coffee Break

Section XI: Aiming at the Future of Medicine

10:20 a.m.  Part 1. The Future of Health Education Starting at Pre-School
Approach in 50,000 Children, at Short, Middle and Long Term

10:40 a.m.  Part 2. Cognitive Impairment and Dementia in the Elderly
Vascular, Alzheimer’s & Combination of Both

11:00 a.m.  PAUL DUDLEY WHITE KEYNOTE 2019
Part 3. The Future of a Successful Clinical Journal
An Evolving Website Tool Aiming at Education and Practice

11:30 a.m.  Adjourn